Trial Profile
An Open-label, Prospective, Non-Comparative Study to Evaluate Subjective Well-Being and Responses in Patients With Schizophrenia Who Had Switched to Paliperidone Extended-Release Tablets
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 May 2014
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms POWER
- Sponsors Janssen
- 10 Jan 2012 Actual patient number changed from 234 to 289 as reported by ClinicalTrials.gov.
- 10 Jan 2012 Actual end date Jan 2011 added as reported by ClinicalTrials.gov.
- 10 Jan 2012 Actual initiation date changed from May 2008 to Apr 2008 as reported by ClinicalTrials.gov.